Prostate cancer is a danger to men globally, with the reported cases numbering 1.1 million worldwide and nearly one in thirty-nine men succumbing to it. Of the most common forms of cancer that affect men, behind skin cancer, prostate cancer is the second most frequent.
Yet despite such an aggressive and detrimental disease, that is by nature difficult to treat, scientific and medical advancements may have found the next step in eliminating cancer in deep sea bacteria.
A recent study conducted across 413 men suffering from low risk prostate cancer (Gleason pattern 3) between March of 2011 and April of 2013 in Europe documented in the publication Lancet Oncology, detailed a progressive new laser treatment system, in conjunction with a drug formulated from deep sea bacteria, has yielded promising results.
According to Professor Mark Emberton, one of the researchers who conducted the Padeliporfin vascular-targeted photodynamic therapy study, in conversation with BBC Radio remarked at the high level of successful elimination of prostate cancer, showing that half of all the men who participated in the trial were prostate cancer free.
Currently, the use of radiotherapy and invasive surgery to combat prostate cancer usually creates a plethora of side effects that ultimately can result in weaker bladders, erectile and bowel dysfunction, and infertility. However, this new form of therapy is incredibly noteworthy for its ability to produce minimal effects towards patients. According to the study,
“Padeliporfin vascular-targeted photodynamic therapy is a safe, effective treatment for low-risk, localised prostate cancer. This treatment might allow more men to consider a tissue-preserving approach and defer or avoid radical therapy.”
These kinds of treatments go a long way in understanding more effective methods to treating all forms of cancer, with photosesitizing methods proving to be an amazing new way to fight the war on cancer.
Together we’ll keep prostates strong and us living long.